Royalty Pharma plc(RPRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | - | P/E | 34.49 | EPS (ttm) | 1.88 | Insider Own | 6.32% | Shs Outstand | 445.8M | Perf Week | 7.5% |
| Market Cap | 28.85B | Forward P/E | 11.15 | EPS next Y | 9.18% | Insider Trans | -2.25% | Shs Float | 418.4M | Perf Month | 11.3% |
| Enterprise Value | 39.93B | PEG | 1.05 | EPS next Q | 1.18 | Inst Own | 85.82% | Short Float | 3.08% | Perf Quarter | 8.04% |
| Income | 0.81B | P/S | 11.38 | EPS this Y | 10.17% | Inst Trans | 1.48% | Short Ratio | 4.29 | Perf Half Y | 30.49% |
| Sales | 2.54B | P/B | 4.23 | EPS next 5Y | 10.61% | ROA | 4.27% | Short Interest | 12.89M | Perf YTD | 67.68% |
| Book/sh | 15.33 | P/C | 34.47 | EPS past 3/5Y | 163.11% -7.26% | ROE | 12.36% | 52W High | 0.64% ($64.38) | Perf Year | 73.89% |
| Cash/sh | 1.88 | P/FCF | 9.58 | Sales past 3/5Y | 2.06% 2.3% | ROIC | 5.29% | 52W Low | 80.4% ($35.92) | Perf 3Y | 137.76% |
| Dividend Est. | $1.02 (1.58%) | EV/EBITDA | 25.18 | EPS Y/Y TTM | -18.25% | Gross Margin | 99.81% | Volatility(W/M) | 1.98% 2.09% | Perf 5Y | 71.67% |
| Dividend TTM | 0.92 | EV/Sales | 15.74 | Sales Y/Y TTM | 9.99% | Oper. Margin | 62.33% | ATR (14) | 1.37 | Perf 10Y | - |
| Dividend Ex-Date | 2026/11/13 | Quick Ratio | 2.8 | EPS Q/Q | -43.58% | Profit Margin | 32.13% | RSI (14) | 72.88 | Recom | 1.5 |
| Dividend Gr. 3/5Y | 5.01% 24.01% | Current Ratio | 2.8 | Sales Q/Q | 16.5% | SMA20 | 9.32% ($59.27) | Beta | 0.37 | Target Price | $66 |
| Payout | 49.4% | Debt/Eq | 1.31 | Earnings | 2026/11/4 | SMA50 | 8.27% ($59.84) | Rel Volume | 1.3 | Prev Close | $63.86 |
| Employees | 100 | LT Debt/Eq | 1.26 | EPS/Sales Surpr. | 3.82% 1.85% | SMA200 | 22.91% ($52.71) | Avg Volume(3M) | 3.00M | Price | $64.79 |
| IPO | 2020/6/16 | Option/Short | Yes/Yes | Trades | 35011 | Volume | 3,909,090 | Change | 1.46% |
💊 Royalty Pharma is a licensing capital investment company that acquires royalty rights to revenue from new drugs and therapies from biotech and pharmaceutical companies to secure long-term cash flow. With a unique business model that does not bear the risks of in-house drug research and development while continuously receiving a share of the revenue from the global commercialization of new drugs, it manages a diversified royalty portfolio spanning various therapeutic areas.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
Next earnings report: November 4
9 days to go. The ex-dividend date is November 13.
RPRX earns at a steady pace
Of every $100 in sales, $62.33 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.2% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $3,449. Peers typically go for $3,400. Compared with its own 5-year average, it is 30% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +71.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 1.58% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 85.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #8 of 594 in the industry
Based on market cap of $29B.
ALNY#7 Alnylam Pharmaceuticals Inc $30B PER 38.4 
RPRX#8 Royalty Pharma plc $29B PER 34.5 
GMAB#9 Genmab ADR $27B PER 35.4 
ROIV#10 Roivant Sciences Ltd $26B PER - 
INCY#11 Incyte Corp $23B PER 14.4 
FAQ
What kind of company is RPRX?
RPRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RPRX?
The market cap of RPRX is approximately $28.8B, ranking 472 within its sector.
Does RPRX pay dividends?
RPRX has a dividend yield of approximately 1.58%, with an annual dividend of $1.02.
What is the P/E ratio of RPRX?
RPRX has a P/E ratio of approximately 34.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RPRX?
RPRX has recorded a 52-week high of $64.38 and a low of $35.92.
